“…the board of directors of Jubilant Pharmova in its meeting held today, i.e., June 12, 2025, at 03:00 P.M. and concluded at 03:28 p.m., inter alia, considered and approved sale and transfer of the Active Pharmaceutical Ingredients (API) business of the company (Undertaking) on a slump sale basis to Jubilant Biosys Limited (JBL), a wholly-owned subsidiary company, engaged in providing drug discovery services to global Pharmaceutical and Biotech companies,” according to a stock exchange filing.
The API division recorded a turnover of ₹609 crore in FY25, accounting for 8.35% of the company’s consolidated revenue. Its net worth stood at ₹666.5 crore as of March 31, 2025, contributing 10.68% of the company’s consolidated net worth.
Also Read: Bhartia family likely to offload stakes in three Jubilant companies via block deals
The transfer is expected to be completed by September 1, 2025, subject to the terms set out in the business transfer agreement. The consideration for the transfer will be based on the book value of assets and liabilities as on the appointed date. The transfer will be done primarily through the issuance of shares.
The transaction qualifies as a related party deal since Jubilant Biosys is a wholly-owned subsidiary. However, the company said the transaction is being executed at arm’s length.
The sale is being carried out outside a Scheme of Arrangement, and compliance with Regulation 37A of the SEBI Listing Regulations is not required, as Jubilant Biosys’ accounts are consolidated with those of Jubilant Pharmova.
Also Read: Jubilant Pharmova’s arm Jubilant Cadista gets USFDA EIR with VAI status for its Maryland facility
Shares of Jubilant Pharmova Ltd ended at ₹1,125, down by ₹19.90, or 1.74%, on the BSE.
